EUCTR2007-006773-92-IT进行中（未招募）不适用
Sodium Valproate in the treatment of medication overuse headache: a controlled randomized clinical trial. - SAMOHA
IVERSITA' DEGLI STUDI DI PERUGIA0 个研究点开始时间: 2008年4月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Subjects, both genders, aged 18-60 years (inclusive) at study entry - Subject, has an established history of episodic migraine without aura in the past; - Subject has an average of at least 15 days per month with headache during the last 3 months preceding the entry into the study; - Headache fulfils ICHD-IIR criteria for MOH (see Appendix 1); -If the medication overused is a simple analgesic the included subject must have used this symptomatic drug on > 15 days per month, for at least 3 months. If the medication overused is a triptan, or a combination of analgesic or a combination of acute medications, the included subject must have used the above drugs on > 10 days per month, for at least 3 months. (see Appendix 2); - Subject judged to be reliable and agreeable to keeping all appointments for clinic visits, tests, and procedures required by the protocol. - Subject, or their legal representatives, must have signed and dated the informed consent; - A female is eligible to enter and participate in this study if she is: a) non-childbearing potential i.e. physiologically incapable of becoming pregnant, including any female who is post-menopausal (> 1 year since last menstrual cycle ), had a documented tubal ligation or is surgically sterilized); b) childbearing potential, has a negative pregnancy test ?urine (at screening), and agree to one of the following: 1. Complete abstinence from intercourse from 2 weeks prior to administration the investigational product, throughout the treatment period and for a minimum of one week after completion or premature discontinuation from investigational product. 2. Consistent and correct use of an acceptable method of birth control
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A subject will not be eligible for inclusion in this study if any of the following criteria apply: - Subject has taken a headache-prevention medication during the month preceding enrolment in the trial. - Known allergy, sensitivity or intolerance to study drugs and/or study drugs? formulation ingredients; - Known allergic reactions to drugs; - Subject used prohibited concomitant therapy [other antiepileptics; barbiturates; antidepressants; some antibatterial drugs (Carbapenem, Panipenem, Meropenem, Imipenem and Erythromycin); anticoagulants; Neuroleptics; Zidovudine, Mefloquine, cytostatics, Cimetidine, Colestiramine, and chronic use of Acetyl-salicylic Acid and benzodiazepines]; - Subject has a history or suspicion of alcohol abuse or illicit drug use in the past 2 years; - Subject has a history of poor compliance with past drug therapies, or is felt to be at risk of non-compliance (for taking study medication or for completing the diary) as judged by the Investigator; - Subject is pregnant or breastfeeding female. For women with childbearing potential, absence of pregnancy must be confirmed by a pregnancy test at study entry; - Subject is female of childbearing potential without adequate contraception; - Subject with a past or present history of a serious illness, which as judged by the Investigator, may affect the outcome of this study. These diseases, in the six months prior the screening, include: liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological (including epilepsy), metabolic disturbances; - Clinically significant abnormalities in safety laboratory analysis at the Screening Visit. Particularly any liver function test (including ALT, AST and ALP) > 1.5 x upper limit normal (ULN) at the screening visit; - Subject is concurrently participating in another clinical study or investigational drug trial or has participated within the previous 30 days in an investigational drug study or is planning to participate in another drug or device study at any time during the study (screening through follow-up).
研究者
相似试验
已完成
2 期
Study of a new medicine combination in ovarian cancer which has come back after initial therapyCTRI/2020/01/022781JIPMER27
招募中
不适用
comparing 2 tablets for treating fits in childreCTRI/2019/04/018520JIPMER
已完成
不适用
Aripiprazole effect in the treatment of maniaBipolar Disorder type I.Bipolar affective disorderIRCT201510222166N2niversity of Social Welfare and Rehabilitation Sciences40
尚未招募
2 期
Comparison of efficacy of Sodium Valproate versus Levetiracetam in Status EpilepticusCTRI/2022/02/040689AIIMS PATNA
已完成
3 期
The effect of intravenous sodium valproate versus dexamethasone on acute migraine headacheAcute migraine headache.Migraine with or without auraIRCT201202199014N1Vic-Chancellor of Research and Technology, Hamadan University of Medical Sciences72